HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat breast cancer in early trial
Disease control OngoingThis study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II or III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New combo therapy aims to keep breast cancer from coming back
Disease control OngoingThis study tests whether a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy can prevent breast cancer from returning after surgery. It includes about 393 people with early-stage, hormone receptor-positive, HER2-positive breast cancer that has no…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
Experimental immune cell combo targets Hard-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a new two-part treatment for people with advanced breast cancer that has not responded to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of a biologic drug (ABBV-461). The m…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for hard-to-treat breast cancer subtype
Disease control OngoingThis study tests whether adding the targeted drug pyrotinib to standard chemotherapy can improve outcomes for people with a specific type of early breast cancer (HR-positive, HER2-low). About 160 participants will receive either the combination or chemotherapy alone before surger…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New drug DS-1062a tested in humans for first time against advanced cancers
Disease control OngoingThis study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC